8-K filing — TELA Bio, Inc. (TELA)
Filed: 2026-10-06 AccNo: 0001104659-26-114042 Size: 186 KB Item 8.01: Other Events
Stocks · News reference
TELA Bio Announces $17M Annual Expense Reduction Through 20% Workforce Streamlining and Resource Optimization, Extending Cash Runway Into 2028
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
TELA Bio announced FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh device for soft tissue reinforcement. Liora is the first fully resorbable synthetic product in the company's portfolio to be designed and produced in-house at its ISO 8 certified cleanroom in Malvern, PA, expanding TELA Bio's soft tissue reconstruction market footprint.
TELA Bio Says FDA Cleared Liora Resorbable Surgical Mesh For Soft Tissue Reinforcement
Craig-Hallum Initiates Coverage On TELA Bio with Buy Rating, Announces Price Target of $2
Craig-Hallum analyst Chase Knickerbocker initiates coverage on TELA Bio (NASDAQ:TELA) with a Buy rating and announces Price Target of $2.